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ABSTRACT

QUANTIFYING POLYPHARMACY IN DIABETES PATIENTS IN THE U.S.

By Jing Tao, BPharm, M. S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2011.

Major Director: David A. Holdford, Ph.D.
Associate Professor, Department of Pharmacy

Objectives: To quantify polypharmacy and assess the socio-economic predictors of medication
use and expenditure in diabetics.

ix

Methods: This study analyzed adult diabetes patients using a nationally representative sample in
Medical Expenditure Panel Survey in 2006. Top ten most highly utilized drug classes were
identified. Descriptive statistics were used to portray the patients’ medication utilization and
spending. Generalized linear models were conducted to assess the socio-economic variants in
drug use and spending.
Results: On average, a diabetes patient had 45 prescriptions in 2006, for total annual spending
of $3,161. A diabetes patient used drugs from 3.43 classes within top ten drug classes. Races and
insurance coverage are associated with drug use and spending, holding other factors constant.
Conclusion: Diabetes patients use multiple classes of drugs. Insurance coverage and races are
related with drug spending and utilization. More research is needed to evaluate the potential risks
of drug-drug interactions due to polypharmacy.

x

CHAPTER 1
Introduction

1.1 Background
Diabetes mellitus is a group of chronic diseases characterized by hyperglycemia. According
to the World Health Organization’s (WHO) definition, diabetes mellitus describes a metabolic
disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin
action, or both. Generally, diabetes is categorized into four clinical classes: (1) Type 1 diabetes,
(2) Type 2 diabetes, (3) Other specific types of diabetes, and (4) Gestational diabetes. Type 1
diabetes was previously called insulin-dependent diabetes because it usually strikes children and
young adults. This form of diabetes results from destroyed pancreatic β-cell which is the only
cells in the body that make the hormone insulin that regulates blood glucose. To survive,
patients with Type 1 diabetes must have insulin delivered by injection or a pump. In adults, type
1 diabetes accounts for 5% to 10% of all diagnosed cases of diabetes [1]. Type 2 diabetes results
from a progressive insulin secretary defect on the background of insulin resistance. Type 2
diabetes is by far the most common type of diabetes. In adults, type 2 diabetes accounts for
about 90%-95% of all diagnosed cases of diabetes [1]. This form of diabetes was previously
called noninsulin-dependent diabetes. It usually begins as insulin resistance, a disorder in which
insulin is not used properly in the body. As the need for insulin rises, the pancreas gradually
loses its ability to produce it. Type 2 diabetes is often associated with older age, obesity, family
history of diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. Other
specific types of diabetes result from other causes such as infections, diseases of the exocrine

1

pancreas, surgery, and drug- or chemical-induced diabetes. This type of diabetes accounts for
only 1% to 5% of all diagnosed cases [1]. Gestational diabetes mellitus (GDM) is a form of
glucose intolerance that is newly diagnosed during pregnancy [2] [3]. This type of diabetes is
more common among obese women and women with a family history of diabetes. During
pregnancy, it requires treatment to normalize maternal blood glucose levels to avoid
complications in the infant. Despite the difference in pharmaceutical treatment for type 1 and
type 2 diabetes, both share similar complications. Diabetes is highly associated with
cardiovascular complications such as coronary heart disease (CHD), large plaque burden and
myocardial infarction (MI) [4]-[6]. Other diabetic-related complications include nephropathy,
neuropathy, and retinopathy [7].
Diabetes has reached epidemic proportions in the United States. According to the most recent
report from Center for Disease Control and Prevention (CDC), 25.8 million Americans have
diabetes and an estimated 79 million adults have pre-diabetes [2]. The disease and its
complications is one of the most expensive medical conditions in the US and ranks seventh as a
leading cause of death in the nation [2]. Economically, diabetes imposes an increasing economic
burden on national health care systems. Research has reported that the total costs of diagnosed
diabetes in the United States in 2007 were $174 billion [8]. After adjusting for demographic
differences, average medical expenditures among people with diagnosed diabetes were 2.3 times
higher than for nondiabetics [8]. The increasing diabetes prevalence, the complexity of its
complications, and the high cost of the treatment, presents challenges to diabetes management
and cost control.
Pharmaceutical intervention plays an important role in preventing the progression of diabetes
complications such as the cardiovascular disease [9]. Pharmaceuticals are used to provide tight
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control of blood glucose levels, blood pressure, and cholesterol levels [10]. Intensive glycemic
control with insulin therapy in type 2 diabetes patients can delay the onset and progression of
diabetic retinopathy, nephropathy and neuropathy [11]. Similar benefits have been shown in
therapies for individuals with type II diabetes [12]. The UK Prospective Diabetes Study indicated
that intensive control of blood pressure and blood glucose reduce the risk of complications in
type 2 diabetes patients [13][14]. A randomized placebo-controlled trial in UK reported that
cholesterol lowering medication can significantly reduce the major coronary events, strokes and
revascularisations [15]. The STENO-2 study indicated that diabetes patients significantly benefit
from an intensified, targeted intervention including using ACE Inhibitors or ARBs, smoking
cessation and dietary interventions [16]. The underlying pathology of cardiovascular diseases in
diabetes patients is complicated and likely multi-factorial. Consequently, several therapeutic
medications should be considered into the comprehensive diabetes care beyond glucose control.
Based on these results, clinical practice guidelines have recommended a more intensive form
of diabetes care with multi-targets of medical care. Multiple drug therapy is generally required
in the treatment for complications for patients with diabetes. For glycemic control, the American
Diabetes Association (ADA) recommends that A1C targets be below or around 7% for diabetes
due to the strong association between A1C level and macrovascular complications [2]. For
hypertension, the blood pressure target has been lowered from 130/85 mmHg to 130/80 mmHg
based upon ADA recommendations [10]. The ADA also recommended that patients with high
blood pressure ≥140/90 mmHg should receive pharmacologic therapy including either an ACE
inhibitor or an angiotensin II receptor blocker (ARB), supplemented with a thiazide diuretic if
necessary [2]. For dyslipidemia in diabetes, statin therapy is recommended to achieve a LDL
cholesterol level < 100mg/dl (2.60 mmol/l), regardless of baseline lipid levels [2]. Additionally,
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anti-platelet agents may also be considered as a primary cardiovascular risk prevention strategy
for elderly diabetic patients. Recommended therapy includes aspirin (75-162 mg/day) for those
who at increased cardiovascular risk or clopidogrel (75 mg/day) and aspirin for those who had an
acute coronary syndrome history [2].
Each of the guidelines and clinical recommendations indicates the likelihood that
comprehensive treatments of diabetic patients will involve several medications across different
therapeutic drug classes. Hence, polypharmacy, which is defined as the prescriptions of multiple
medications simultaneously [20], has become a salient consideration in the care of patients with
diabetes. The major consequences of polypharmacy for diabetes patients include adverse drug
reactions (ADRs), drug-drug interactions, increased drug costs, decreased medication adherence,
potential duplicated therapy, as well as additional demands for health care services and decreased
quality of life [17]. It is noted that with the accelerating rate of drug cost increasing, the financial
burden of larger drug regimens may become particularly important for the society. It has been
suggested that patients’ regimens should be regularly reviewed and evaluated in order to achieve
optimum control of medical problems as well as to keep lower drug costs.

1.2 Objectives and specific aims
The aim of this research was to study the patterns of medication prescription in a nationally
representative cohort of adult diabetic patients in 2006. The primary goal was to describe the
number of prescriptions and drug classes used among diabetes patients on a personal level, and
to quantify the spending on the diabetes-related medications. The secondary goal was to assess
socio-economic variants in this patient population.
The study has following specific aims:
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Specific aim 1: To list top ten drug classes by utilization among diabetes patients.
Specific aim 2: To describe the demographic characteristics (age, gender, and race) of the patient
sample.
Specific aim 3: To calculate the average total drug cost, average out-of-pocket payment, and
average number of prescriptions, and average number drug classes.
Specific aim 4: To evaluate the socio-economic predictors of medication use and drug spending
among the diabetes patients, controlling for age, gender, race, geographic regions, marital status,
general health perception and co-morbid diseases.

1.3 Significance
There is abundant evidence that tight control of glucose, blood pressure, and cholesterol levels
decreases the risk of developing diabetes and its related macro- and microvascular complications
and cardiovascular death [7] [13] [14] [18] [19]. On the other hand, the undesired consequences of
multiple medications for diabetes have been described [20]-[23]. This includes adverse drug
reactions, medication errors and increased risks of nonadherence and hospitalization rates.
The complexity of diabetes therapy on a personal level (number of medications undertaken)
provides important implications for the safety of patients and quality of diabetes management as
well as drug cost control. Documenting the average number of prescriptions and number of drug
classes by each patient is important for public health concerns with respect to polypharmacy.
Addressing the socio-economic inequalities regarding multi-pharmacy use and medication
expenditures provides a better understanding for policy makers on strategies for diabetes
management.
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To our knowledge, however, there has been few study focused on detailed quantification of
the level of complexity based on the therapeutic drug classes [10] [24]. The literature gap is
discussed in Chapter 2. This study contributes to the literature that quantifies multiple
therapeutic drug classes used on a patient level and its socio-economic determinants as they
influence the patterns of patients’ medication utilization.
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CHAPTER 2
Literature Review

2.1 Epidemiology of Diabetes
Current data show that we have been in the midst of a global epidemic of diabetes. Shaw and
his colleagues, using the International Diabetes Federation (IDF) data, estimated that 285 million
adults suffering from diabetes worldwide in 2010. This means that the global prevalence of
diabetes is 6.4%, and it is predicted that the prevalence will reach 7.7% among adults by 2030 [25].
After adjusted for age and gender, the highest regional prevalence for diabetes in 2010 was for
North America, followed by the Eastern Mediterranean and Middle-East (EMME) and South
Asia [25]. The United States has the largest numbers of people with diabetes, followed by India
and China, the two nations with the largest populations in the world [25].
According to the recent report from U.S. CDC, 25.8 million Americans have diabetes and 79
million adults have pre-diabetes. Pre-diabetes as defined by the American Diabetes Association
as a condition in which blood glucose levels are higher than normal but not high enough to be
diagnosed as diabetes[2]. An estimated 90-95% of diagnosed diabetes is the noninsulindependent type 2 form of the disease which is characterized by insulin resistance, or the inability
of cells to effectively use insulin [1]. A report of the National Diabetes Fact Sheet for 2011
indicated that diabetes affects 8.3% of Americans of all ages and 11.3% of adults aged 20 years
and above [26].
Geography, age and race affect the prevalence of diabetes. In the U.S., there is a
geographically coherent region of 15 southern states called the diabetes belt, where the
prevalence of diagnosed diabetes is especially high [27]. The prevalence of diabetes in the
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diabetes belt was reported as high as 11.7% in 2007-2008 [27], compared to the national
prevalence of 7.8% in the same year [1]. Regionally, using the National Health and Nutrition
Examination Survey (NHANES) database in 2003-2007, Danaei estimated that the lowest
prevalence of diabetes was in the Midwest and the Northeast with the age-standardized
prevalence ranging from 11.0% to 12.2% for men and 7.3% to 8.4% for women [28]. The highest
prevalence was in the southern and Appalachian states where age-standardized diabetes
prevalence was 15.8% to 16.6% for men and 12.4% to 14.8% for women [28]. Danaei also
reported that age-standardized diabetes prevalence was higher in men than women in all states,
with the largest differences in Minnesota, Colorado, Utah, and Maine, where prevalence in men
was 32% to 38% higher than that in women (Figure 2.1) [28].
Racial variance in diabetes prevalence in adults has been shown where 7.1% of nonHispanic
whites, 8.4% of Asian Americans, 11.8% of Hispanics, and 12.6% of nonHispanic blacks have
diagnosed diabetes in 2007-2009 [26]. Furthermore, compared to nonHispanic white adults, the
risk of diagnosed diabetes was 18% higher among Asian Americans, 66% higher among
Hispanics, and 77% higher among nonHispanic blacks [26].
The prevalence of diabetes increases with age. The prevalence of diabetes among individuals
aged of 20-44, 45-64 and ≥65 years old were 3.7%, 13.7% and 26.9%, respectively (Figure 2.2)
[2]

. Compared to younger persons 44 years and younger, older patients over 65 years have more

than 7 times the prevalence of diabetes.
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Figure 2.1: Estimated prevalence of total diabetes by state, sex and age group
(age-standardized to the 2000 U.S. population) [28]
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Figure 2.2: Estimated percentage of people aged 20 years or older with diagnosed and
undiagnosed diabetes, by age group, United States.
(Source: 2005-2008 National Health and Nutrition Examination Survey) [2]

2.2 Economic burden of diabetes
The growing number of diabetics and the costs of treatments for the disease and its
complications have significant economic impact. The total estimated direct medical costs and
lost productivity was $174 billion in 2007 in the United States [29]. Direct medical costs
attributed to diabetes include hospital inpatient care, diabetes medications and supplies, retail
prescriptions to treat complications of diabetes, and physician office visits. Inpatient care
accounts for 50% of total medical expenditures, followed by diabetes medication and supplies,
which accounts for 12% [29]. Indirect costs resulting from lost productivities due to diabetes were
estimated as $ 58 billion, including absenteeism, reduced productivity while at work for the
employed population, reduced productivity for those not in the labor force, unemployment from
disease-related disability, and lost productive capacity due to early mortality. Averagely, people
with diagnosed diabetes have medical expenditures that are up to 2.3 times higher than what
10

expenditures would be in the absence of diabetes [29]. Other factors that are attributable to the
economic burden of diabetes include higher insurance premiums paid by employees and
employers, reduced earnings through productivity loss, and reduced overall quality of life for
patients with diabetes and their families. On average, a US male diagnosed as having diabetes at
age 40 years will lose almost 12 life-years and 19 quality-adjusted life-years (QALYs) compared
with a person of the same age without diabetes. Similarly, a US female diagnosed as having
diabetes at age 40 years will lose about 14 life-years and 22 QALYs [30].
Indeed, the burden of diabetes is imposed on all sectors of society. Much of the cost is
preventable through improved diabetes management, initiated to reduce the prevalence of
diabetes and costly complications.

2.3 Risk factors for diabetes population
While the prevalence of diabetes can provide information about the burden of disease in the
community, prevalence rates do not capture individuals’ risks of developing diabetes. The
variation in diabetes prevalence across states, ages and races indicates that diabetes is strongly
affected by behavioral, cultural, and environmental factors clustered and overlaid on genetic
susceptibility. Individual level of risk factors for diabetes include genetic predisposition,
race/ethnicity, increased body mass index (BMI), physical inactivity, and some medical
conditions associated with diabetes such as cardiovascular disease and obesity.
Individuals at higher risk for diabetes include: (1) those with impaired glucose tolerance (IGT)
and/or impaired fasting glucose (IFG); (2) people over age 45; (3) those with a family history of
diabetes; (4) people who are overweight; (5) people who do not exercise regularly; (6) people
with low HDL cholesterol or high triglycerides, high blood pressure; (7) Certain racial and ethnic

11

groups such as NonHispanic Blacks, Hispanic/Latino Americans, Asian Americans and Pacific
Islanders, and American Indians and Alaska Natives); and (8) women who had gestational
diabetes, or who have had a baby weighing 9 pounds or more at birth [31].
Race is a strong independent risk factor for diabetes. Diabetes is over twice as prevalent
among African-American adults as compared to their white counter-parts, with odds ratio (OR)
=2.35 [32]. Some risk factors such as race, BMI, and socioeconomic status (SES) are associated
with each other, presenting a combined impact on developing diabetes. A higher incidence of
diabetes is reported among African American women in lower SES versus higher SES
neighborhoods [33], increased BMI among women in areas of high unemployment relative to
areas of low unemployment [34]. For overweight persons whose BMI was between 25-29.9,
ethnic disparities worsened as diabetes prevalence increased 33% in Whites, compared to 60% in
Blacks, and 227% in Mexican Americans [35]. Some investigations also indicate higher rates of
diabetes in rural areas relative to urban centers [36] [37], because socioeconomic factors such as
education, income and health insurance status are strongly related to health and vary between
rural and urban settings, and these factors contribute to health differences [37]. Health insurance
status is important because it is related to income as well as health patterns. Lower income level
contributes to a higher proportion of that is uninsured or poorer health insurance overages,
resulting in lower level of access to the health care services.
Hence, a variety of factors contribute to the onset and management of diabetes disease,
including demographic, geographic, socioeconomic factors and clinical information as well.
Factors such as age, races/ethnicities, education, income, health insurance status, health
perceptions, and lifestyles have impacts on the disease management and health care service

12

utilization. Understanding the diabetes epidemic and management must take into account a
complex array of multiple risks such as individual, social, economic, and environmental factors.

2.4 Diabetes Complications
The population burden of diabetes complications is large in terms of mortality, morbidity, and
loss of quality of life. Diabetes is such a serious disease in that it can results in blindness, kidney
failure, peripheral neuropathy and arterial disease, cognitive impairment, and death [38]. The
pathobiology of diabetic complications is generally featured as hyperglycemia-induced tissue
damage, shown in Figure 2.3 [39]. Although the damage process can be modified by both genetic
determinants of individual susceptibility and independent accelerating factors such as
hypertension, some cell types are particularly susceptible to be damaged by hyperglycemia
because they are not efficient in reducing the transport of glucose inside the cell when they are
exposed to hyperglycemia. These cell types include: capillary endothelial cells in the retina,
mesangial cells in the renal glomerulus, and neurons and Schwann cells in peripheral nerves [39].
Hence, diabetes selectively damages cells such as endothelial cells and mesangial cells.
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Figure 2.3: General features of hyperglycemia-induced tissue damage [39]

2.4.1Morbidity
The morbidities of diabetes include cardiovascular disease, eye, kidney, and lower-extremity
disease, acute metabolic complications and disability [26] [38].
Cardiovascular disease
In the United States in 2004, heart disease and stroke were noted on 68% and 16%,
respectively, of diabetes-related death certificates among people ages 65 years or older [26]. In
2005-2008, 67% of adults aged 20 years or older with diabetes had hypertension, which is
defined as blood pressure greater than or equal to 140/90 mmHg [26]. The prevalence of ischemic
heart disease among patients with diabetes varies by age groups.
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The prevalence rate of heart disease was about 14 times the rate among those without diabetes
in persons 18 to 44 years of age, 3 times as high in persons 45 to 64 years of age, and almost
twice as high in those 65 years of age or older [38]. Other studies have shown that the rates of
cardiovascular disease in diabetes patients are also different by patients’ gender. The absolute
rates are reported to be higher in men than in women, while the relative risk is higher in women
than in men, comparing those with and without diabetes [41] [42].

Eye, Kidney, and Lower-Extremity Disease
Diabetes retinopathy is the leading cause of new cases of blindness among adults [26] [40]. A
cross-sectional study on a nationally representative sample of the National Health and Nutrition
Examination Survey in 2005-2008 estimated a crude prevalence of diabetic retinopathy and
vision-threatening diabetic retinopathy was 28.5% and 4.4%, respectively, among older persons
with diabetes aged above 40 years [43]. Vision loss due to diabetic retinopathy occurs through a
variety of mechanisms, including retinal detachment, preretinal or vitreous hemorrhage,
associated neovascular glaucoma, and macular edema or capillary nonperfusion [44]. Other cause
of vision impairment among persons with diabetes include macular edema which is specific to
diabetes, cataracts and glaucoma that are not specific to diabetes but occur more commonly in
diabetic than in nondiabetic persons [45]-[47].
Diabetes is the leading cause of end-stage renal disease (ESRD), nontraumatic lower-extremity
amputations (LEAs) as well [48]. Diabetes is a major cause of chronic kidney disease (CKD) [49],
and diabetic nephropathy accounted for 44% of all new cases of end-stage renal disease in 2008
[26]

. The precise pathophysiologic basis for the association between deteriorating kidney function

and diabetes disease is unclear. But it is suggested that poorly controlled glucose levels, blood
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pressure, and cholesterol activate inflammatory mediators, and patients with a genetic
predisposition may help progressing to advanced stage nephropathy [49].
Lower-extremity disease, which includes peripheral neuropathy and peripheral arterial disease
or both, results in elevated rates of lower-extremity amputations among persons with diabetes.
More than 60% of nontraumatic lower-limb amputations occur in people with diabetes [26].
People with diabetes have been found to have 2 to 3 times the prevalence of either peripheral
neuropathy symptoms or insensate feet [50].

Acute Metabolic Complications
The acute metabolic complications of diabetes consist of diabetic ketoacidosis (DKA),
hyperosmolar nonketotic coma (HNC), lactic acidosis (LA) and hypoglycemia [51]. DKA and
HNC are related to insulin deficiency resulting in the metabolic outcome of very low levels of
effective insulin action [51] [52]. DKA is clinically defined by absolute insulin deficiency with
hyperglycemia, while HNC is defined by the presence of relative insulin deficiency. LA is
usually related to other factors such as cardiovascular diseases, and hypoglycemia mostly results
from the treatment of diabetes.
Only the incidence rate of DKA is available from population-based studies. It is estimated that
DKA is more common in young diabetic people and may be more common in women than men
[51]

. Except hypoglycemia, the other three metabolic complications of DKA, HNC, and LA

require hospitalization for treatment and thereby result in increased use of health care resources
and costs.

Nervous System Disease
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Diabetic neuropathies are among the most frequent complication of long-term diabetes. About
60 to 70 percent of patients with diabetes have mild to severe forms of nervous system damage
[26]

.

The femoral nerve is commonly involved giving rise to symptoms in the legs and arms,

and pain is the chief symptom that tends to worsen when patients are at rest. It is estimated that
almost 30 percent of diabetes patients aged over 40 years old have impaired sensation in the feet
[26]

. Furthermore, advanced femoral nerve disease is a major cause of lower extremity

amputations.

Other Diabetes Complications
Other complications such as depression, susceptibility to other illnesses, are found higher rates
among diabetes patients compared to other population. Depression is an independent risk factor
for the onset of type 2 diabetes [51]. Not only can it complicate diabetes management, but also
negatively affects the course of diabetes and is associated with increased risk of complications [53]
[54]

. There has been a growing call to understand the medical and psychosocial challenges that

highlights the importance of concerning about mental health of the diabetes patients.
Besides, diabetes patients are found to be more susceptible to other illnesses, such as
pneumonia and influenza. Most of the time, they have worse prognosis than patients without
diabetes [26].

2.4.2 Mortality
Diabetes was the seventh leading cause of death based on U.S. death certificates in 2007 [2].
This estimate is based on the 71,382 death certificates in which diabetes was the underlying
cause of death [26]. Furthermore, diabetes was a contributing cause of death in an additional

17

160,022 death certificates for a total of 231,404 certificates in the same year in which diabetes
appeared as any-listed cause of death [26]. Studies also suggested that death certificates
underestimate the prevalence of diabetes among decedents [55].

2.5 Goals of drug therapy for Diabetes
Effective glycemic control is the main goal of diabetes therapy [2]. However, the nonglycemic
goals for diabetes management are of paramount importance as well, especially for the
management for cardiovascular complications because they are the major cause of mortality in
patients with diabetes [18].

2.5.1 Glycemic goals
The recognition of the efficacy in substantially reducing morbidity by achieving specific
glycemic goals has made the effective treatment of hyperglycemia a priority in diabetes
management [2] [56] [57]. Intensive treatment strategies have been demonstrated to reduce
complications of both type 1 and type 2 diabetes [7] [13] [14]. The goals of glycemic control are set
differently by different organizations. The American Diabetes Association suggested a general
glycemic goal of lower than 7% in glycated hemoglobin (A1C) level for nonpregnant adults [2],
while the American Association of Clinical Endocrinologists (AACE) and the American College
of Endocrinology (ACE) recommend A1C level of ≤ 6.5% [58]. In general, studies have shown
that maintaining glycemic levels as close to the nondiabetic range as possible has been
demonstrated to have a powerful beneficial effect on reducing complications such as retinopathy,
nephropathy, neuropathy, and cardiovascular disease (CVD) in diabetes patients [59].
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Blood glucose-lowering medications are available for both type 1 and type 2 diabetes.
However, oral blood glucose-lowering medications can only be used for patients with type 2
diabetes. These oral medications include sulfonylureas, meglitinides, the biguanide, metformin,
thiazolidinediones, alpha-glucosidase inhibitors, and the oral dipeptidyl-peptidase-4 inhibitor
sitagliptin[60]. The increased number of choices available to physicians and patients has
heightened concern whether used alone or in combination with other blood glucose-lowering
interventions are most appropriate for the individual patients [59] [61]. Overall, the ADA and the
European Association for the Study of Diabetes (EASD) published a consensus statement that
the main objective of hyperglycemia management is to achieve and maintain glycemic control
and to change interventions when therapeutic goals are not being met [2].

2.5.2 Nonglycemic goals
The nonglycemic goals for diabetes management refers to the prevention and management of
diabetes complications, among which cardiovascular disease is the major cause of morbidity and
mortality for diabetes individuals and the largest contributor to the medical costs of diabetes.
The genesis of cardiovascular complications is in pre-diabetic states, and studies have shown that
strict glycemic control is effective in preventing and delaying the development of CVD [18]. The
CVD treatments include controlling hypertension, elevated low-density lipoprotein (LDL),
prothrombotic state and cigarette smoking. The goals of these treatments are listed in Table 2.1,
according to the ADA statement on standards of medical care in diabetes 2010 [2] [18].
Other nonglycemic goals include nephropathy, retinopathy, neuropathy treatment and food
care. ACE inhibitors or ARBs are recommended for the treatment of the nonpregnant patient
with albuminuria, which is an early marker of chronic kidney disease (CKD) [62], and is
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associated with a higher risk of renal function loss [63]. The management of painful
polyneuropathy is focused on symptom relief and positively improving the quality of life [2]. For
example, gastroparesis symptoms may improve with prokinetic agents such as metoclopramide
or erythromycin; medications for erectile dysfunction may include phosphodiesterase type 5
inhibitors, intracorporeal or intraurethral prostaglandins [2].
Table 2.1 Treatment goals for CVD in adult diabetes patients [2] [18]
Hypertension/blood pressure control

< 130/80 mmHg
LDL cholesterol: < 100mg/dL

Dyslipidemia control

HDL cholesterol: >50 mg/dL
Triglycerides: < 150 mg/dL

Prothrombotic state control

Aspirin therapy: 75-162 mg/day as primary prevention
strategy in adult diabetes patients and macrovascular
disease or for primary prevention in patients older
than 40 years with diabetes or with more than one
other CVD risk factor.

Cigarette smoking goal

Cessation

2.6 Polypharmacy Regimen for Diabetes and Literature Gap
Most diabetes patients take oral medications instead of insulin to control glucose level. It is
estimated that only 12% adult patients with diabetes take insulin only, while 58% take oral
medication only (Figure 2.4) [26].
Polypharmacy can be defined as the use of two or more medications simultaneously [20]. The
characteristics of diabetes and its complications often require a multiple medication regimen for
diabetes, frequently using drugs from multiple therapeutic classes. However, the risks of
polypharmacy and the potential inappropriate medication use must be considered and balanced
against the benefits of multiple drug therapies. Simultaneous use of multiple medications is
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often associated with drug-drug interactions, adverse drug reactions, medication errors, and
increased risks of nonadherence to therapeutic regimens and higher hospitalization rates,
especially for elderly patients who are suffering from decreased renal and hepatic functions [20][23]

.

Figure 2.4 Percentage of adults with diagnosed diabetes receiving treatment with insulin
or oral medication, United States, 2007-2009
(Source: 2007-2009 National Health Interview Survey) [26]

Surprisingly, although the risks of multiple medication use are well recognized, most studies
on polypharmacy have merely focused on the levels of adherence to the medication therapy [19]
[64] [65]

and the association between the adherence level and clinical control of LDL, A1C, and

blood pressure level [66] [67]. An inverse relationship was evidenced between the number of drugs
prescribed and patients’ adherence to diabetes-related medications, resulting a significantly
lower A1C and total cholesterol level at the end of the study period [19]. Successful control of
clinical targets depended highly on a subject’s baseline number of treatments. The number of
medications among successful cases was 11 to 17 percentages lower than those failed to achieve
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the clinical targets [67]. However, these studies have typically not characterized the drug regimens
in terms of a detailed description of therapeutic drug classes used to treat patients with diabetes.
Grant et al provided evidence that treatment related to diabetes care has grown more complex
over time [24]. Using the National Ambulatory Medical Care Survey (NAMCS), they
characterized trends in the number of prescribed medicines, management of hyperglycemia,
hypertension, and hyperlipidemia from 1991 to 2000. Significant increases were found in the
number of prescription medicines reported at office visits over time (Figure 2.5). The unadjusted
proportion of patients prescribed at least 5 medications increased in a linear trend from 18.2% in
1991 to 29.9% in 2000 (p<0.001), as shown in Figure 2.5. After controlling for age, gender,
race/ethnicity, insurance status, physician type, the diabetes type and visit duration, the
proportion of patient visits with 5 or more medicines increased by 10.1% per year from 1991 to
2000 (95% CI, 6.6%-13.5%; p < 0.001).

Figure 2.5 Trends in the total number of prescribed medicines, 1991-2000 [24]

Increases were also found in the use of medications for antihypertension and lipid level
lowering (Figure 2.6). In similar regression models controlling for patient and physician
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characteristics and visit duration, the proportion of prescribing antihyperglycemia medications
did not change significantly (p>0.05), but that of prescribing antihypertension and
antihyperlipidemia medications resulted in significant increases, with an increase of 12.9% and
19.1% per year, respectively.

Figure 2.6 Trends in pharmaceutical treatment of hyperglycemia, hypertension, and
hyperlipidemia, 1991-2000 [24]

However, this study was not able to provide a basic description of trends in the number of
medications used by diabetes patients. The unit of the analysis was the visit instead of the patient,
so the medication care at an individual level was not assessed. Furthermore, the study placed a
cap on the total number of medications (5 medications) for each visit, so the average number of
medications was not determined.
Huang et al assessed the trends in diabetes regimens from 1995 to 2003, using 30 managed
care plans in Midwest and Southern regions [10]. To evaluate the complexity of medication
regimens, they calculated the average number of medications and the proportion of patients
receiving diabetes-related medications (blood glucose, blood pressure, and cholesterol control
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agents). On a patient level, they noted a significant increase in the average total number of
diabetes-related medications among patients with prescribed medications (from 2.96 to 3.70,
p<0.01), with smaller increases seen for glucose lowering (from 1.45 to 1.65, p<0.01) and blood
pressure lowering regimens (from 2.14 to 2.51, p<0.01). Regarding the proportion of patients on
the three types diabetes-related medications, they reported a dramatic rise in the proportion on
cholesterol lowering (18% to 39%, p<0.01) and antihypertension agents (51% to 62%, p=0.04),
adjusted for age, age-squared, female and interactions of female with age variables (Figure 2.7)
[10]

.

Compared with Grant’s study, Huang assessed the average number of medications and
percentage of patients using three major drug categories of diabetes regimen. Nevertheless, the
results of this study could not be generalized to the whole country because the study sample was
not nationally representative. Besides, only three diabetes-related drug classes (cholesterol
lowering, antihypertension and glucose lowering agents) were taken into account in this study.
Even though cardiovascular diseases are important complications of diabetes, there are more
treatments for diabetes patients in order to take care of other complications such as depression,
neuralgia and kidney diseases. Thus, the complexity of regimen for diabetes patients needs to be
comprehensively assessed. Moreover, they did not access to the actual risk factor levels, such as
geographic, demographic, health insurance status, and other socio-economic factors. Our
knowledge is sparse with respect to identifying individuals who are particularly prone to
polypharmacy therapies. Overall, we do not know the extent of complexity of the regimens and
financial burden of medical therapy in diabetes patients.
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Figure 2.7 Adjusted trends in (A) the proportion of patients with any or specific types of
diabetes drugs, and (B) the total number of diabetes related drugs conditional on any use of
drugs [10]

Based upon the prior literature, this study uses a recent and nationally representative dataset.
The therapeutic drug classes among diabetes patients are broadened from 3 to top ten categories
that are used among diabetes patients on patient level. Individual factors that have impacts on
diabetes regimen and drug expenditures are evaluated as well, so as to give an extensive
understanding of the complexity of diabetes treatment. The factors affecting individual’s
medication use and drug expenditure are discussed in Section 2.7.
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2.7 Socio-economic predictors of medication use and expenditure
Within the multicultural context of the United States, inequalities in health services utilization
and consumption is a concern in this country. Differences in drug use and expenditures are
based on race/ethnicity, gender, age, income, insurance status, geographic location, sexual
orientation, occupation, or health behaviors. Disparities among the different segments of the
population have been defined in terms of differences in health status, risk factors for disease and
injury, access to and use of health care services, access to health insurance, and differences in the
quality of care received [68]. Reasons for the inequalities in health care included differences in
risk factors, lack of access to health care, inadequately targeted prevention messages, and
cultural differences.
In the United States, the first national report on health care quality and disparity was released
by the Agency for Healthcare Research and Quality (AHRQ) in 2003. It demonstrates a broad
picture of the scope and characteristics of differences in health care quality and access associated
with patient gender, age, race, ethnicity, income, education, and location [69] [70]. They reported
that racial and ethnic minorities and poor people often receive poorer quality of care and face
more barriers when trying to access health care [70].
In this study, we focus on the demographic, geographic and related socio-economic variants in
prescribed medication use and spending among adult patients with diabetes. These factors are
overlapped and influence each other.

2.7.1 Demographic variants
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The United States is an ethnically and racially diverse nation. The current population is
approximately 67% nonHispanic White, 12% black, 14% Hispanic, 1% American Indian/Alaska
Native, and 4% Asian (Figure 2.8) [71].

Figure 2.8 Percentage of United States population, 2005 [71]

There have been abundant studies reporting that racial/ethnic minorities and poor people use
fewer medications and poorer quality of heath care. Compared with whites, nonwhites including
African Americans, Latinos, and Asian/Pacific Islanders often have poorer glycemic control [72].
Another study reported that the rates of medication underuse were highest among African
Americans and Latinos [73]. The current proposed mechanisms for racial/ethnic disparities in
medication use are physiologic, socioeconomic, cultural in nature. The median family annual
income for nonHispanic Whites and Asians is $20,000 to $25,000 higher than for Blacks,
Hispanics, and American Indians/Alaska Natives in 1999 [71]. Hence, patients with higher
education and income are able to purchase better health insurance coverage and to obtain more
access to and high quality of healthcare services. The Hispanic population is estimated to be
27

much younger on average than the other demographic groups, with a median age of 25.8 years
compared with 38.6 years for the white population in 2000 [71]. As a result, it is likely that
Hispanics consume less health care than other groups and are underrepresented in research on the
use and quality of health care. Besides, social determinants such as cultural beliefs in drug
regimens and medical conditions may result in differences in medication adherence.
Gender may contribute to the difference in medication utilization and consumption. The
imbalance between men and women exists with respect to health care utilization related costs. In
general, women tend to use significantly more health care services and spend more health care
dollars than men [74]. An analysis of Express Scripts’ integrated database of medical and
pharmacy claims demonstrated that women contribute to 60% of medical spending and consume
59% of the prescription volume [75].
Age has notable impacts on medication use as well. Elderly patients have higher risks of
complications and side effects of medications due to their decreased liver and renal functions [20]
[76]

. Diabetes is such a chronic disease that the normal aging process can change the way

medication are absorbed, metabolized and distributed in the body.

2.7.2 Geographic variants
Geographic factors influence not only the prevalence and incidence of diabetes, but the
medication use among diabetes patients as well. Rural residents have disparities in access to care
compared with urban residents because of distance to health care facilities [77]. The impacts of
geographic factors on medication use may overlap with that of race/ethnicity. Since Blacks or
Hispanic populations tend to live in different areas from nonHispanic white populations, location
matters in the measurement of health care disparities.
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In this study, both geographic region and metropolitan statistical area (MSA) status are
included to predict the variation in drug use and spending among adult diabetes patients.

2.7.3 Impacts of health insurance coverage
Health insurance coverage is an important determinant for medication use and spending, and it
is strongly related to better clinical outcomes as well [78]. Health insurance status reflects a
variety of social and economic status of the patients. Income level, employment status,
citizenship status, and language play roles in disparities in insurance coverage, and thus impacts
the access to care and quality of care [79].
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CHAPTER 3
Methodology

3.1 Data Source
The data used in this study were derived from the 2006 Medical Expenditure Panel Survey
(MEPS) Full Year Consolidated Data Files and the 2006 MEPS Prescribed Medicines (PMED)
Files. The datasets were obtained from their official website which is maintained and cosponsored by the Agency for Healthcare Research and Quality (AHRQ) and the National Center
for Health Statistics (http://www.meps.ahrq.gov/mepsweb/).
MEPS, which was initiated in 1996, is a nationally representative longitudinal survey of
families and individuals, their medical providers (doctors, hospitals, pharmacies, etc.), and
employers across the United States [80]. MEPS is a survey of panel design, which is featured by
five rounds of interviews covering two full calendar years [81]. The survey collects detailed
information on health care utilization and expenditures, health insurance, and health status, as
well as a variety of social, demographic, and economic characteristics for the civilian
noninstitutionalized population. MEPS consists of two major components: household
component (MEPS-HC) and insurance component (MEPS-IC). MEPS-HC collects data for each
person on demographic characteristics, health conditions, health status, health insurance
coverage, income, and employment. MEPS-HC data are available on MEPS Web site in data
tables. MEPS-IC, which is also known as the health insurance cost study, collects data including
the types of private insurance plans offered, premiums, contributions by employers and
employees, and benefits associated with these plans. However, IC data files are not available for
public release. In this study, we only used MEPS-HC data file.
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Two data files were used from the household component: 2006 Full Year Consolidated Data
File and 2006 Prescribed Medicines File. Data were obtained in Rounds 3, 4, and 5 of Panel 10
and Rounds 1, 2, 3 of Panel 11, covering calendar year 2006, as illustrated in Figure 3.1.

Figure 3.1: Survey rounds for MEPS panels covering calendar year 2006 [81]

The consolidated data file contains 1672 variables, pertaining to survey administration,
demographics, employment, health status, disability days, quality of care, patient satisfaction,
health insurance, income and person-level medical care use and expenditures. About 34,145
persons participated in MEPS Household Component of medical expenditure panel survey in
2006 [81]. This count includes all household survey persons who resided in eligible responding
households. Of these persons, 32,577 persons were assigned a positive person-level weight. In
this study, only the observations with positive person-level weight are used in the analysis.
Observations with zero person-level weights were deleted.
In the prescribed medicine file, counts of prescribed medicine utilization are based entirely on
household reports. Persons with no prescribed medicine use for 2006 are not included on this file.
The prescribed medicine dataset contains 341,994 records of prescribed medicine. Of these
prescribed medicine records, 336,109 records are associated with persons having positive
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person-level weight. Diabetic supplies, such as syringes and insulin, are also included in the data
of MEPS prescription drug expenditure and utilization. Each record on the prescription file
includes an identifier for each unique prescribed medicine, national drug code (NDC), medicine
name, selected Multum Lexicon variables, total expenditure and sources of payments. Multum
Lexicon variables are derived from Multum Lexicon database at Cerner Multum. Inc, which is a
global company, providing updated databases for drug information. We used Multum Lexicon
variables to identify the drug classes that are used among the sample population.
In this study, the two data files were merged with each other by linking the unique person
identifier, variable DUPERSID. By using the person-level weight variable (PERWT06F), the
analyses were able to make estimates for the civilian noninstitutionalized U.S. population for
2006.

3.2 Study Sample
The study sample was nonpregnant diabetes patients who are older than 18 years of age.
Patients were eligible for inclusion based on their answers to whether they have ever been
diagnosed with diabetes (ICD-9-CM codes 249, 250) [81]. Patients with gestational diabetes were
excluded. A total of 2,189 patients claimed to have been diagnosed as diabetes. These patients’
demographic information from consolidated data file was then linked with their prescribed
medication records from prescribed medicine data file for analyses.
Information from the last rounds of Panel 10 and Panel 11 in the year 2006, in order to obtain
the most accurate number of patients who have diabetes. Using the previous rounds information
may exclude those patients who potentially have diabetes but were not diagnosed during the
earlier rounds.
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Due to the dataset limitation, we were not able to differentiate between patients with Type 1
and Type 2 diabetes. Albeit we were able to exclude part of the Type 1 diabetics by limiting
only adult patients included in this study, we may still have some Type 1 diabetes who used
insulin only without other oral anti-diabetic medications in our sample. Thus our estimates on
medication use may be underestimated.

3.3 Variables
The MEPS database contains a wide range of demographic and clinical variables for analysis.
These variables include age, gender, race, geographic region, metropolitan statistical area (MSA),
marital status, education year, family income as percent of poverty line, family size, insurance
coverage status, health perception, medical condition, medication use, and medication
expenditure.
Categorical variables were created for some demographic information such as age groups,
race/ethnicity, marital status, insurance coverage status, health perception and co-morbid
diseases. For age groups, patients were divided into three categories: 18-44, 45-64 and 65-85
years of age, according to the age categorization of ADA [2]. Medication use among diabetic
patients is age-related due to the progress of diabetes disease and complications. Patients over
65 years old are more likely to use multiple medications than younger individuals [20] [62]. For the
race/ethnicity variable, the study sample was categorized into seven groups: White Hispanic,
White nonHispanic, Black, Asian, American Indian, Hawaiian and multiple races. Hispanic
Nonwhite patients were differentiated from Hispanic White individuals on account of the fact
that Hispanics share distinguished cultural beliefs, habits, income level, and education level from
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nonHispanic population. These racial/ethnic differences may contribute to variance in
medication use among diabetes population.
The variable of health insurance coverage was categorized into Medicare Part D, Medicare
nonpart D, Medicaid, Private insurance coverage, and self-payers. Each patient was assigned to
only one category of insurance type. A hierarchy according the primary payer was used for
people who enjoyed coverage from more than one source. Medicare coverage had first place in
this hierarchy. For instance, if a person was covered by Medicare and Medicaid or private
insurance, he or she was categorized as having Medicare coverage regardless of any other
coverage, because Medicare is the primary payer for his or her drug benefit. Same as other
example, if someone had both Medicare non-Part D and private insurance, then the person was
classified as having private insurance group as his primary payer is private insurance. The other
two categorical variables that were created in this study were general health perception and comorbid diseases. Both of these two clinical factors contribute to a variation in medication use
and thus affect drug spending. Patients with poor health perception and more co-morbid diseases
are more likely to experience polypharmacy.
Two indicator variables (family size, education year) were created to identify people who lived
alone and who received at least a high school education. Family size and education are
associated with medication compliance. Patients who live with their families have better
adherence to their medications. Well-educated people are considered to have better knowledge
about the therapeutic regimen and may enjoy higher income as well [71]. Hence, people who live
with families and well educated are more likely to be adherent to prescriptions.
Twelve independent variables were used in a multivariable regression model to assess the
impacts on the three study outcomes of medication use and costs (Table 3.1). As for the
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variables of health perception and comorbidites, only the information from the last rounds of
Panel 10 and 11 (Figure 3.1) was used. As explained before, the health status and co-morbid
diseases are progressing over time. In order to avoid the potential changes in health status and
progress of comorbid diseases during the year, the information obtained at the end of the year
was used in this study. The 12 independent variables and 3 dependent variables are listed in
Table 3.1. In multivariate regression model, the largest group in each independent variable was
set to be the reference group.
Table 3.1 –Variables in multivariate model
Variables

Descriptions

Independent variables
Age

18-44, 45-64, 65-85

Gender

Male, Female

Race

White Hispanic, White nonHispanic, Black, Asian, American
Indian, Hawaiian, Multiple race

Region

Northeast, Midwest, West, South

MSA status

MSA, NonMSA

Marital status

Married, Widowed, Divorced, Separated, Never married

Family size

=1, >1

Education Year

≤11 years, ≥12 year

Family income as percent of
poverty line

Poor/negative, Near poor, Low income, Middle income, High
income

Health Insurance Coverage

Medicare part D, Medicare nonpart D, Medicaid, Private
insurance coverage, Self-pay

Health Perception

Excellent, Very good, Good, Fair, Poor

Comorbidities

Asthma, High cholesterol, Angina, Coronary heart disease,
Heart attack, Other heart disease, Stroke, Arthritis,
Emphysema, High blood pressure
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Dependent variables
Total drug costs per person per year
Out-of-pocket payment per person per year
Number of therapeutic drug classes used per person per year

3.4 Identification of Top Ten Therapeutic Classes
Top ten therapeutic drug classes in total utilization with greatest number of prescriptions were
identified among our study sample. The therapeutic classes have been identified by the Multum
Lexicon variable: TCnSn, a therapeutic sub-classification variable [82]. As explained in the
documentation for MEPS prescribed medicine file, the Multum Lexicon variables are derived
from the Multum Lexicon database at Cerner Multum, Inc, which is a leading global company
providing information management in healthcare [83]. Drugs are organized into three levels:
therapeutic level (TCn), pharmacological level (TCnSn), and specific drug category level
(TCnSn_n) [82]. The variable TCnSn is a sub-classification variable of TCn, assigning one or
more sub categories to a more general therapeutic class category and sub-category given to a
drug. For example, the TCn level category includes general therapeutic classes such as antiinfectives, then it is subdivided into pharmacological classes such as cephlosporins, penicillins,
quinolones. Cephlosporins can be further subdivided into specific drug categories such as first to
fourth generation cephlosporins (Figure 3.2).
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Figure 3.2 Example of Multum drug classification

3.5 Outcomes of Interest
This study aimed to assess the medication use and expenditure among diabetes patients in the
year 2006. Medication use was defined at two levels: number of prescription filled and
therapeutic drug class used in the defined year. At the prescription level, medication utilization
was defined by prescriptions filled over the course of the year. At the therapeutic drug class
level, medication use was defined as one or more purchases of a medication in a therapeutic class
of the top ten drug classes. For this purpose, the assessed outcomes include: (1) the yearly
average number of prescriptions filled per person; and (2) the yearly average number of drug
classes used per person.
Medication expenditures were assessed with respect to (1) total drug cost per patient, and (2)
out-of-pocket (OOP) spending per user. Out-of-pocket spending refers to the amounts paid by
individual patients other than any insurance sponsors. Premiums for insurance were not included
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in OOP calculations in this study. Total drug cost included all payments by individuals (out-ofpocket payments), private insurance, Medicaid, Medicare, and other types of insurance.
Taking into account the risk factors in the prevalence of the diabetes as well as the patterns of
drug use, socio-economic variables were evaluated in medication use of top ten drug classes and
medication expenditures at the personal level. As introduced before, 12 independent variables
were included in the multivariate regression model to examine the effects of each included factor
on the outcomes of (1) total drug cost, (2) out-of-pocket, and (3) number of therapeutic drug
classes used on an the patient level (Table 3.1).

3.6 Statistical Analysis
The top ten drug classes in utilization among diabetes patients were identified by sorting the
number of prescriptions for each therapeutic drug class. We conducted descriptive analysis in
evaluating medication utilization and expenditure on a patient level. For the drug expenditure,
we calculated the averages of total drug cost, out-of-pocket spending per person per year. The
total annual drug spending was charted for the top ten drug classes in 2006. The drug utilization
per person per year was calculated based on the number of prescriptions and number of drug
classes used by each patient. The percentages of patients using the top ten drug class were also
calculated for each therapeutic class.
Generalized linear modeling (GLM) was used to conduct the multivariate regression. We had
three dependent variables in terms of the drug spending (total spending and OOP) and top ten
drug classes utilization. Due to the positively skewed distributions of the outcomes, we used a
generalized Gamma distribution with a log link to fit the model, in order to obtain more unbiased
estimates of the impact of the set of predictors [84]. In the statistical model selection, the model
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with a log link was superior to those with other functions of link such as reciprocal because it
came out with the smallest deviance value, based upon the same degrees of freedom. In 2001,
Manning and Mullahy suggested that the ordinary least square (OLS) estimates can be notably
less precise and biased than some of the GLM alternatives, when the distribution is not bellshaped or a skewed bell-shaped [84]. Furthermore, the interpretation of the results is relatively
straightforward using GLM, compared to OLS with log transformation.
To illustrate, the formula used in this study is shown below. The response variable Y is
linearly associated with values of the explanatory variables by:
Y  b0  b1 Age  b2 Gender  b3 Race  b4 Re gion  b5 MSA  b6 Marital  b7 Familysize 
b8 Education  b9 Povertylev el  b10 Insurance  b11Healthperc eption
 b1221 (Comorbidities )  e

where the e stands for the error term, while the relationship in the generalized linear model with
log link is:
log( muY )  b0  b1 Age  b2 Gender  b3 Race  b4 Re gion  b5 MSA  b6 Marital  b7 Familysize
 b8 Education  b9 Povertylev el  b10 Insurance  b11Healthperc eption
 b12 21 (Comorbidities )

where muy stands for the expected value of Y. The log link function links the expected values of
Y to the regressors and determines the model.
All the data were weighted to reflect the drug utilization and expenditure of the whole
population in the United States. Stata 10 was used to conduct all the analyses, using significance
level of 0.05.
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Chapter 4
Results

4.1 Study population
A total of 2,189 patients were identified in this study, representing 17.5 million diabetes
patients in the United States in 2006. The mean age of patients was 63 years of age, 56.01% of
the patients were women, and 49.06% were White-NonHispanic (Table 4.1). The majority of the
study population was elderly patients, given that only 14.62% of the patients were younger than
45 years old. In our study sample, there were 12 patients who were diagnosed with diabetes but
did not have any purchase records of prescription medicines. However, in order to obtain an
accurate number of diagnosed diabetes patients and medication use patterns, these 12 patients
were included into our analyses.

Table 4.1 - Population Characteristics
Unweighted
Patient Characteristics
Weighted Frequency (%)
Frequency (%)
Age
≤44
45-64
≥65

320 (14.62%)
1,043 (47.65%)
826 (37.73%)

2,370,273.09 (13.51%)
8,424,204.89 (48.03%)
6,745,717.32 (38.46%)

Male
Female

963 (43.99%)
1,226 (56.01%)

8,651,271.02 (49.32%)
8,888,914.27 (50.68%)

White-Hispanic
White-NonHispanic
Black
Asian
American Indian or Alaska
Native
Multiple Races
Native Hawaiian or Pacific
Islander

501 (22.89%)
1,074 (49.06%)
468 (21.38%)
74 (3.38%)

2,255,218.19 (12.86%)
11,352,405.40 (64.72%)
2,672,013.36 (15.23%)
566,821.59 (3.23%)

32 (1.46%)

324,642.65 (1.85%)

27 (1.23%)

243,241.93 (1.39%)

13 (0.59%)

125,852.23 (0.72%)

Gender

Race
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Unweighted
Frequency (%)

Patient Characteristics

Weighted Frequency (%)

Region
Noreast
Midwest
South
West

333 (15.21%)
412 (18.82%)
897 (40.98%)
547 (24.99%)

3,210,862.52 (18.31%)
3,698,500.68 (21.09%)
6,968,094.42 (39.73%)
3,662,737.66 (20.88%)

Non-MSA
MSA

480 (21.93%)
1,709 (78.07%)

3,737,994.14 (21.31%)
13,802,201.10 (78.69%)

≤11
≥12

798 (97.06%)
1,355 (62.94%)

4,741,580.24 (27.32%)
12,611,139.80 (72.68%)

Married
Widowed
Divorced
Separated
Never married

1,232 (56.28%)
371 (16.75%)
336 (15.35%)
60 (2.74%)
190 (8.68%)

10,378,177.10 (59.17%)
2,768,054.92 (15.78%)
2,658,680.2 (15.16%)
379,034.63 (2.16%)
1,356,248.42 (7.73%)

=1
>1

491 (22.43%)
1,698 (77.57%)

4,088,380.98 (23.31%)
13,451,814.30 (76.69%)

Poor
Near poor
Low income
Middle income
High income
Health Insurance Coverage
Medicare part D
Medicare nonpart D
Medicaid
Private insurance coverage
Self-pay
General Health Perception
Excellent
Very good
Good
Fair
Poor

451(20.60%)
196 (8.95%)
405 (18.50%)
584 (26.68%)
553 (25.26%)

2,315,372.80 (13.20%)
1,137,674.62 (6.49%)
2,794,879.61 (15.93%)
5,203,709.76 (29.67%)
6,088,558.49 (34.71%)

594 (27.14%)
408 (18.64%)
203 (9.27%)
696 (31.80%)
288 (13.16%)

4,215,645.81 (24.03%)
3,815,136.68 (21.75%)
1,087,827.44 (6.20%)
6,852,033.68 (39.06%)
1,569,551.68 (8.98%)

99 (4.52%)
373 (17.04%)
778 (35.54%)
645 (29.47)
293 (13.39)

921,799.06 (5.26%)
3,443,171.32 (19.63%)
6,324,391.18 (36.06%)
4,806,581.64 (27.40%)
2,037,142.09 (11.61%)

MSA status

Education year

Marital status

Family size

Poverty level
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4.2 Top ten therapeutic classes
The top ten drug classes in utilization among diabetes patients were: antihyperlipidemic agents,
angiotensin converting enzyme inhibitors (ACE Inhibitors), beta-Adrenergic blocking agents,
calcium channel blocking agents, diuretics, antihypertensive combinations, analgesics,
antidiabetic agents, antidepressants, and proton pump inhibitors.

4.3 Annual drug utilization
On average, a diabetes patient had 45.34 (median=36) prescriptions (Table 4.2), and 3.43
(median=3) classes of drugs within the top ten drug classes (Table 4.3). However, the
distribution of prescription counts was skewed. The maximum number of prescriptions was as
high as 253 per person per year, using all of the top then drug classes throughout the year (Figure
4.1 and Figure 4.2).

Table 4.2 – Description of number of prescription per person in 2006
Mean

Min

25%

50%

75%

Max

45.34

1

18

36

61

253

Table 4.3 – Description of number of drug classes used per person in 2006
Mean

Min

25%

50%

75%

Max

3.43

0

2

3

5

10
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15
10
5
0

% of the population

0

50
100
150
200
number of prescriptions per person per year

250

15
10
5
0

% of the population

20

Figure 4.1 Distribution of number of prescription used per person per year

0

2
4
6
8
number of top ten drug classes used by person per year

10

Figure 4.2 Distribution of number of drug classes used per person per year
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Regarding the top ten drug classes, about 83.9% of the patients used antidiabetic agents in
2006, and 52.6% used antihyperlipidemic agents, followed by analgesics, ACE inhibitors and
Beta-blockers, with percentage of 39.6%, 37.4%, and 28.3%, respectively. Details are shown in
Figure 4.3.

Figure 4.3 - Percentage of Patients Using the Top ten Drug Class in 2006 (Weighted)

4.4 Annual drug expenditure
On average, a diabetes patient incurred a total of $3,161 (sd = 4235.1) for prescribed
medicines and spends $1,061 (sd = 1323.43) for out-of-pocket costs annually in 2006. The top
ten categories accounted for 61.4% of the total drug spending for diabetics. Figure 4.4 shows
44

weighted annual total spending of the top ten drug classes. Antidiabetic and Antihyperlipidemic
agents were the top two drug classes that cost the most, accounting for 24.1% and 13.5% of the
total annual drug expenditure, respectively.
One outlier in the sample had 253 prescriptions used that cost a total of $117302.5. Out-ofpocket spending for this patient was $20076.29. This total was verified and the cause appeared
to be due to significant analgesic use. This outlier was kept in the sample because the patient
was alive on the last day of the study period and met the requirements for inclusion.

Figure 4.4 – Annual total expenditure of top ten drug classes in 2006 (Weighted)
(Note: the numbers on the top of the bars are the percentage of each drug class spending
out of total drug expenditure)
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4.5 Multivariate regression analysis outcomes
Tables A-1to A-3 (Appendix) show the results from multivariate regressions. Race, marital
status, and health insurance coverage were significant predictors in total drug spending among
diabetes patient in year 2006. Compared to White-NonHispanic people, Asians spent 42% less,
American Indians/Alaska Natives 39% less, and Native Hawaiians/Pacific Islanders 65% less
total drug spending, all with p <0.05. Compared to married people, separated individuals spent
45.9% less on drugs, p=0.009. Differences in drug spending are also revealed with respect to
health insurance coverage status. Compared to patients with Medicare Part D, patients with
Medicare NonPart D, Private insurance coverage and those without drug coverage had lower
total drug spending, accounting for 17%, 48%, and 74% less spending, respectively, each with
p<0.01.
Out-of-pocket spending was associated with age, gender, race, and health insurance coverage
among diabetes patients (Table A-2). Compared to elderly patients over 65 years, patients
younger than 44 years old had 30.9% lower OOP payment (p=0.017), but patients between 45
years old and 64 years did not have significant difference in OOP payment from older adults.
Males spent 14% less OOP than female patients, with p=0.016. Asians, American
Indians/Alaska Natives, and Native Hawaiians/Pacific Islanders had lower OOP payment than
White NonHispanic people. Asians were 61% lower, American Indians/Alaska Natives were
51% lower, people of multiple race background were 49% lower, and Native Hawaiians/Pacific
Islanders were 97% lower than the comparison group, respectively, all with p<0.05. For health
insurance coverage, self-payers spent 40.89% more OOP than Medicare Part D beneficiaries
(p=0.003), while Medicaid beneficiaries had 26.5% lower OOP payments compared with
Medicare Part D enrollees.
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Regarding the number of top ten drug classes used per person per year, predictors of age,
gender, race, and health insurance coverage showed significant variances among diabetes
patients (Table A-3). Compared with older adults over 65 years, patients younger than 44 years
old used 10.6% fewer drug classes, while patients between 45 to 64 years old used 9.09% more
drug classes, both with p<0.05. Male patients used 5.3% fewer drug classes than females,
p=0.016. This is supported by findings that females tend to use more medicine than males [74] [75].
Compared to White NonHispanic patients, White Hispanics used 9.2% fewer drug classes, p =
0.008. Regarding health insurance coverage, not surprisingly, patients with private insurance
and those without drug coverage used fewer drug classes than patients with Medicare Part D,
20.7% and 33.2% fewer, respectively, p<0.001, holding everything else constant. The number of
drug classes used by patients was associated with the total drug costs and out-of-pocket
payments. Patients without drug insurance tend to use fewer drug classes, spent less on total drug
spending but had to pay more by themselves than Medicare Part D beneficiaries. Private
insurance beneficiaries spent less on total drug spending, took fewer medications than Medicare
Part D beneficiaries, but their out-of-pocket payments did not have significant difference.
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Chapter 5
Discussion

5.1 Main findings
Diabetes is a progressive and complex metabolic disorder with a set of complications that
make it necessary to undertake polypharmacy for patients. In this nationally representative
cross-sectional study, we identified the top ten drug classes used most by diabetes patients.
These drug classes include Antihyerlipidemic agents, Angiotensin converting enzyme inhibitors
(ACE Inhibitors), Beta-Adrenergic blocking agents, Calcium channel blocking agents, Diuretics,
Antihypertensive combinations, Analgesics, Antidiabetic agents, Antidepressants, and Proton
pump inhibitors. This finding is in line with the strategies of prevention and treatment of
diabetes and diabetes-related complications such as vascular and neuropathic diseases.
Among the top ten therapeutic drug classes, antidiabetic agents were used by 83.9% of
diabetes patients, and accounted for 24.1% of the total spending on drugs among diabetics in
2006. Antidiabetic medications, also called antihyperglycemic agents, treat diabetes mellitus by
lowering blood glucose levels. Generally, patients are required to undertake monotherapy or
combination of antidiabetic agents in order to achieve the goal of blood glucose lowering to a
clinically safe range, as recommended by the clinical guidelines [2]. A large body of evidence
have demonstrated that combination therapy appear to be more effective than monotherapy in
glucose control [85] [86]. Traditional antidiabetic agents include sulphonylureas, biguanides,
thiazolidinediones, meglitinide analogues, and alpha-glucosidase inhibitors, that control
hyperglycaemia through one or more sites of action [76]. Newer drugs mimic or potentiate the
activities of incretin hormones, including GLP-1 (glucagon-like peptide-1) mimetics and DPP-4
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(dipeptidyl peptidase-4) inhibitors [18]. Despite the benefits of combination therapy of glucose
control, concurrent use of multiple pharmaceuticals of this drug class may raise the risk of
adverse effects of poor adherence and drug-drug interactions, especially for drugs that are
metabolized by the cytochrome P450 (CYP450) system For instance, it has been confirmed that
thiazolidinediones (TZD), meglitinide analogues, and sulphonylureas are subject to potentially
interfere with drugs metabolised with the CYP450 system [87] [88], and may lead to worse
outcomes of cardiovascular complications [89].
Antihyperlipidemic agents are another major group of medications for diabetes patients,
ranking second amongst the top ten therapeutic drug classes in utilization and expenditure for
patients in 2006. Diabetes patients tend to have a characteristic dyslipidemia, making them 2 to
4 times more likely to develop cardiovascular disease than those without diabetes [90]. Even
when effective glycemic control is achieved with antidiabetic treatment, dyslipidemia persists in
many patients with diabetes, especially type 2 diabetes [86]. Antihyperlipidemic agents are used
to control lipid levels. Major antihyperlipidemic medications include HMG-CoA reductase
inhibitors (statins), niacin, fibrates, and bile acid sequestrants [91]. Many statins, except
pravastatin, are primarily metabolized by the cytochrome P450 system [87] [88], and may thus
induce drug-drug interactions based on this mechanism.
There are concerns about multiple medication regimens for diabetes patients. On average, a
diabetes patient used 3.43 drug classes out of the top ten drug classes in this study. Furthermore,
significant variance exists in the number of drug classes used by each patient. About 25% of the
patients in this study used more than 5 drug classes, and 10% used more than 6 drug classes in
2006. The number of concurrent medications may be even larger than then number of drug
classes, because many patients take combination therapy of antidiabetic agents. Earlier studies
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have shown that treatment with two or three drugs may not result in medication problems, but
when the number of drugs exceeds four, patients are exposed to significant risks such as
medication errors, medication noncompliance, and higher rates of hospitalization [92] [93].
On one hand, it is apparent that an increase in the number of co-medications tends to decrease
the adherence of patients to their treatment regimens, and this may result in a more severe
adverse reaction, higher rates of hospitalization and related healthcare costs. On the other hand,
drug-drug interactions are a concern when patients are taking multiple drugs. Studies have found
a positive association between the number of concurrent medications used and the potential for
clinically relevant or potentially serious drug-drug interactions [94] [95]. As mentioned before,
drugs that undergo metabolism by CYP 450 isoenzymes system, such as statins, TDZs are
subject to induce drug-drug interactions if they are administered with some calcium channel
blockers such as verapamil and diltiazem, which inhibit CYP 3A4 [96]. For diabetes patients, the
medications used to treat the complications may adversely affect the control of glucose. For
example, thiazide diuretics may be useful to treat mild to moderate hypertension but may induce
glucose intolerance by diminishing insulin sensitivity [97]. Other drugs for hypertension, such as
Beta-blockers, may inhibit beta-adrenergic stimulation of insulin secretion and mask some
symptoms of hypoglycemia [76]. Especially, we found that 38% of our study population is of 65
years age or older. Older adults are more fragile to these risks of multi-medication regimens.
Physiological changes associated with aging, such as decreased renal and hepatic function,
decreased total body water and decreased lean body mass, requires special consideration in terms
of the dosage and combination of the medications for elderly patients [20] [76].
The patterns of medication use among diabetes patients are potentially influenced by a web of
factors. Indeed, some of these factors are health status related, but demographic and socio-
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economic statuses are also important. In this study, we explored the predictive effects of
race/ethnicity and health insurance overage on the medication use patterns with consideration of
other covariates mediating these effects. After adjusting for other socio-demographic and
geographic factors, including age, gender, education, marital status, family size, region, MSA,
and poverty level, two predictors have demonstrated significant differences with regard to
medication use among diabetes patients. Generally, minorities have profoundly lower drug
spending and use a lower number of drug classes than NonWhite -Hispanics. One possible
explanation for this variation is cultural difference. Ethnic culture affects our beliefs about
health, illness, and medications, and it also influences how we comply with prescribed
medications. Studies indicated that Asian patients are more cautious about American
medications and often initiate downward dosage adjustments to avoid potential adverse drug
reactions [98]. Secondly, certain race or ethnic groups seem to be closely linked to disadvantaged
socioeconomic position in terms of income, education and wealth [99]-[104]. The lower medication
use and spending may somewhat reflect reduced access to health care, limited social support, or
local discriminatory practices. As for health insurance status, apart from the health conditions
and aging factors, moral hazard could be an explanation for the disparities. Patients with
generous pharmaceutical benefits who have more access to medications may have incentive to
use more drugs. In this study, we used a hierarchy classification of the insurance coverage.
Medicare enrollees, even if they have supplemental coverage from private insurance, are
categorized into Medicare group. Hence, patients with Medicare Part D have comparatively
more generous benefits for prescribed medications. These patients seem to have more total drug
spending while less out-of-pocket payments than patients with other coverage, especially those
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with private insurance only and without drug insurance. Meanwhile, Medicare Part D enrollees
are found to use more drug classes than private insurance patients and self-payers.
Compared to previous studies, the results of this study add greater depth to the picture of
diabetes therapy complexity. We identified ten therapeutic drug classes that are mostly used
among diabetes patients. Apart from three major components of diabetes therapies such as
antidiabetic antihyperlipidemic, and antihypertensive agents, other agents, such as analgesics,
PPIs, antidepressants, and diuretics are identified into the top ten drug classes that are used most
often among diabetics, so that we obtained more detailed and comprehensive information about
the medication use among diabetes patients. Instead of using the visit as the unit of analysis, we
used the person as the unit of analysis. We calculated not only the medication use with regards
to number of prescriptions and therapeutic drug classes in a year, but also the economic burden
for individuals in terms of annual total drug spending and out-of-pocket payment. We also
provided evidence that the prescribed medication uses among diabetes patients vary across
different races/ethnicities and different insurance coverage, after adjusting for other socioeconomic factors. This heterogeneity in medication use and spending may reflect differences in
the health care environments and indicates the importance of implementing individualized
treatment strategies for diabetes patients.

5.2 Limitations
This is a cross-sectional study on a representative sample. We described the relationship of
the socio-economic variables with our study outcomes. However, we were not able to establish
causal relationships or obtain reliable perspectives on the outcomes from this study. Secondly,
we used a nationally representative survey dataset to gather demographic information and related
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prescribed medicine records. Some questions cannot be solved, given the limited information
available in the database. For example, we have one outlier in our sample with an extremely
large amount of drug spending and usage, but we have no idea about the reason for these large
values. Furthermore, the sample sizes of certain minorities were too small to be stable.
In addition, prescribed medication use is a crude measure in this study. We can only obtain
the total number of drug classes that are used in the year span. However, we cannot distinguish
between switches and addition of the drugs. For instance, if a diabetes patient used drug class A
and switched to class B later, we count the number of drug classes used as 2. Meanwhile, when
a diabetes patient used drug class A and added class B into his/her regimen later, we still count 2
drug classes used by this patient. Furthermore, we were unable to ascertain each patient’s health
insurance status change. We used the insurance coverage status on the last day of the year for
each patient, which is imprecise. For some people, insurance coverage changes over the year
due to some reasons such as unemployment or retirement. It is complex to grab and take into
account all of these changes.
Last but not least, we studied on the prescribed medication in this project with no regards to
other medicines such as OTC and herbal drugs. MEPS collects drug data prompted to look at
prescribed medicines only. However, this information is important as well. Some analgesics are
OTC drugs, and diabetes patients may not report this information in the survey. Excluding these
medications may provide conservative estimates as well as underestimates of cost and
complexity of diabetes treatment. More importantly, the effects of prescribed medication
therapies may be affected because of drug-drug interactions or changes in the metabolism of the
prescribed drugs [20] [105], which is a potential threat for drug safety.
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5.3 Implications and future directions
The findings in this study are enlightening for patient care purposes. The number of drug
classes that are used by most of the diabetes patients are reaching or already exceeding the
threshold for increased risks of falls, hypoglycemia, and other adverse drug events [10]. Hence,
despite the fact that intensive treatment goals and multiple medications may bring benefits for
diabetes patients, polypharmacy is likely to raise the concern of the risks of ADRs, nonadherence
and drug-drug interactions for clinicians and patients with diabetes. More efforts are needed on
investigating how to optimize the clinical diabetes regimens in purpose to simultaneously
increase the benefits and minimize the undesired consequences of polypharmacy.
Our results are also potentially useful for health policy planning. Heterogeneous medication
use and spending makes it prudent to focus health care quality improvement efforts on patients
with poorer drug coverage or those who are at lower socio-economic positions. For this purpose,
more research is needed on a larger span of study periods, by which we may obtain the trends of
the variance in medication use and spending across different socio-economic positions over time.

5.4 Conclusions
In summary, diabetes patients used multiple therapeutic drug classes in 2006. Antidiabetic
and antihyperlipidemic agents were two classes that were mostly used by diabetes patients and
had higher costs than other categories of medications. We also found significant impacts of
racial/ethnic and insurance coverage status differences on medication utilization and expenditure,
after adjusting for other pertinent covariates among individuals with diabetes mellitus.
Knowledge about the complexity of diabetes therapy and the characterization of the socioeconomic variations will enable quality improvement of diabetes care.
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Appendix
Detailed Multivariate Regression Results
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Table A-1 Weighted multivariate regression in total drug spending per person in 2006
Independent Variables

Coef. (95% CI)

P>|z|

Age
65-85

Referent

18-44

-0.21 (-0.44, 0.02)

0.074

45-64

0.17 (-0.015, 0.36)

0.071

Gender
Female

Referent

Male

-0.058 (-0.16, 0.043)

0.258

Race
White nonhispanic

Referent

White hispanic

-0.14 (-0.31, 0.021)

0.086

Black

-0.13 (-0.28, 0.013)

0.073

Asian

-0.42 (-0.69, -0.14)

0.003*

American Indian or Alaska Native

-0.39 (-0.74, -0.032)

0.033*

Native Hawaiian or Pacific Islander

-0.65 (-1.23, -0.069)

0.028*

Multiple race

0.16 (-0.27, 0.59)

0.47

Region
South

Referent

Northeast

0.11 (-0.03, 0.25)

0.125

West

-0.053 (-0.20, 0.09)

0.47

Midwest

-0.11 (-0.24, 0.021)

0.100

MSA status
MSA

Referent

NonMSA

0.13 (0.0004, 0.24)

0.049*

Education Year
≤ 11

Referent

≥ 12

0.054 (-0.065, 0.173)

Marital status
Married

Referent
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0.376

Marital status

Widowed

-0.073 (-0.25, 0.11)

0.423

Divorced

-0.063 (-0.23, 0.10)

0.447

Separated

-0.46 (-0.81, -0.11)

0.009*

Never married

0.065 (-0.15, 0.28)

0.549

Family size
=1

Referent

>1

0.10(-0.051, 0.25)

0.193

Poverty level
Middle income

Referent

Poor

-0.034 (-0.21, 0.14)

0.702

Near poor

-0.072 (-0.29, 0.14)

0.514

Low income

-0.09a (-0.25, 0.066)

0.255

High income

0.050 (-0.075, 0.17)

0.435

Health Insurance Coverage
Medicare part D

Referent

Medicare nonpart D

-0.17 (-0.31, -0.02)

0.024*

Medicaid

0.24 (-0.024, 0.51)

0.075

Private insurance coverage

-0.48 (-0.68, -0.28)

0.000*

Self-pay

-0.74 (-0.97, -0.50)

0.000*

General Health Perception
Fair

Referent

Excellent

-0.40 (-0.64, -0.17)

0.001*

Very good

-0.19 (-0.33, -0.038)

0.014*

Good

-0.20 (-0.33, -0.080)

0.001*

Poor

0.17 (-0.00063, 0.34)

0.051

Asthma

0.35 (0.20, 0.50)

0.000*

High cholesterol

0.29 (0.19, 0.39)

0.000*

Angina

0.012 (-0.20, 0.22)

0.911

Coronary heart disease

0.25 (0.077, 0.43)

0.005*

Comorbidities
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Comorbidities

Heart attack

-0.11 (-0.30, 0.071)

0.229

Other heart disease

0.16 (0.017, 0.30)

0.028*

Stroke

0.024 (-0.16, 0.21)

0.797

Arthritis

0.12 (0.016, 0.23)

0.025*

Emphysema

0.17 (-0.087, 0.42)

0.198

High blood pressure

0.34 (0.23, 0.45)

0.000*

This model included race/ethnicity, health insurance coverage status as main predictors.
The remaining variables were included as covariates (age, gender, education, region,
MSA status, marital status, family size, poverty level, general health perception, and
comorbidities).
“Referent” refers to the comparison group.
“*” Statistically significant at p<0.05.
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Table A-2 Weighted multivariate regression in out-of-pocket payment per person in 2006
Independent Variables

Coef. (95% CI)

P>|z|

Age
65-85

Referent

18-44

-0.31 (-0.56, 0.058)

0.017*

45-64

0.028 (-0.17, 0.23)

0.788

Gender
Female

Referent

Male

-0.14 (-0.25, -0.026)

0.016*

Race
White nonhispanic

Referent

White hispanic

-0.094 (-0.28, 0.09)

0.326

Black

-0.078 (-0.24, 0.086)

0.353

Asian

-0.61 (-0.92, -0.29)

0.000*

American Indian or Alaska Native

-0.51 (-0.91, -0.11)

.0013*

Native Hawaiian or Pacific Islander

-0.97 (-1.62, -0.32)

0.004*

Multiple race

-0.49 (-0.95, -0.026)

0.038*

Region
South

Referent

Northeast

-0.0016 (-0.16, 0.15)

0.984

West

-0.0017 (-0.16, 0.16)

0.984

Midwest

-0.15 (-0.29, -0.0058)

0.041*

MSA status
MSA

Referent

NonMSA

0.11 (-0.026, 0.25)

0.111

Education Year
≤ 11

Referent

≥ 12

0.15 (0.014, 0.28)

Marital status
Married

Referent
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0.030*

Widowed

0.527 (-0.14, 0.26)

0.527

Divorced

-0.23 (-0.42, -0.047)

0.014*

Separated

-0.35 (-0.74, 0.037)

0.076

Never married

-0.056 (-0.29, 0.18)

0.645

Family size
=1

Referent

>1

0.010 (-0.16, 0.18)

0.910

Poverty level
Middle income

Referent

poor

-0.14 (-0.34, 0.054)

0.156

Near poor

0.031 (-0.21, 0.27)

0.802

Low income

0.013 (-0.16, 0.19)

0.885

High income

-0.029 (-0.17, 0.11)

0.689

Health Insurance Coverage
Medicare part D

Referent

Medicare nonpart D

0.11 (-0.050, 0.27)

0.177

Medicaid

-0.27 (-0.60, 0.038)

0.087

Private insurance coverage

-0.021 (-0.24, 0.20)

0.846

Self-pay

0.41 (0.14, 0.67)

0.003*

General Health Perception
Fair

Referent

Excellent

-0.34 (-0.60, -0.071)

0.013*

Very good

-0.13 (-0.30, 0.039)

0.134

Good

-0.065 (-0.21, 0.08)

0.362

Poor

0.29 (0.10, 0.49)

0.003*

Asthma

0.32 (0.15, 0.49)

0.000*

High cholesterol

0.24 (0.13, 0.36)

0.000*

Angina

0.14 (-0.096, 0.37)

0.250

Comorbidities
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Coronary heart disease

0.14 (-0.057, 0.34)

0.161

Heart attack

0.029 (-0.18, 0.24)

0.784

Other heart disease

0.16 (0.0041, 0.32)

0.044*

Stroke

0.013 (-0.17, 0.22)

0.901

Arthritis

0.043 (-0.081, 0.17)

0.497

Emphysema

0.12 (-0.17, 0.40)

0.419

High blood pressure

0.30 (0.18, 0.43)

0.000*

This model included race/ethnicity, health insurance coverage status as main predictors.
The remaining variables were included as covariates (age, gender, education, region, MSA
status, marital status, family size, poverty level, general health perception, and
comorbidities).
“Referent” refers to the comparison group.
“*” Statistically significant at p<0.05.
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Table A-3 Weighted multivariate regression in number of therapeutic classes used per
person in 2006
Independent Variables

Coef. (95% CI)

P>|z|

Age
65-85

Referent

18-44

-0.11 (-0.20, 0.0092)

0.032*

45-64

0.091 (0.012, 0.17)

0.024*

Gender
Female

Referent

Male

-0.053 (-0.096, -0.0098)

0.016*

Race
White nonhispanic

Referent

White hispanic

-0.092 (-0.16, -0.024)

0.008*

Black

-0.030 (-0.091, 0.031)

0.336

Asian

-0.09 (-0.21, 0.028)

0.133

American Indian or Alaska Native

-0.15 (-0.30, -0.0015)

0.048*

Native Hawaiian or Pacific Islander

-0.24 (-0.48, -0.0046)

0.05*

Multiple race

-0.085 (-0.26, 0.089)

0.338

Region
South

Referent

Northeast

-0.0164 (-0.074, 0.041)

0.574

West

0.020 (-0.038, 0.078)

0.508

Midwest

0.011 (-0.044, 0.066)

0.692

MSA status
MSA

Referent

NonMSA

0.020 (-0.031, 0.71)

0.442

Education Year
≤ 11

Referent

≥ 12

0.032 (-0.018, 0.082)

Marital status
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0.204

Married

Referent

Widowed

-0.12 (-0.19, -0.040)

0.003*

Divorced

-0.087 (-0.15, -0.019)

0.012*

Separated

-0.069 (-0.22, 0.079)

0.360

Never married

0.020 (-0.068, 0.11)

0.659

Family size
=1

Referent

>1

0.093 (0.029, 0.16)

0.005*

Poverty level
Middle income

Referent

Poor

0.045 (-0.028, 0.12)

0.224

Near poor

0.061 (-0.030, 0.15)

0.187

Low income

0.014 (-0.051, 0.079)

0.668

High income

0.011 (-0.041, 0.064)

0.667

Health Insurance Coverage
Medicare part D

Referent

Medicare nonpart D

-0.011 (-0.071, 0.050)

0.724

Medicaid

-0.039 (-0.15, 0.072)

0.488

Private insurance coverage

-0.21 (-0.29, -0.12)

0.000*

Self-pay

-0.33 (-0.43, -0.23)

0.000*

General Health Perception
Fair

Referent

Excellent

-0.092 (-0.19, 0.0064)

0.067

Very good

-0.08 (-0.14, -0.020)

0.009*

Good

-0.037 (-0.089, 0.015)

0.164

Poor

0.015 (-0.057, 0.087)

0.690

Asthma

0.10 (0.039, 0.16)

0.002*

High cholesterol

0.32 (0.28, 0.36)

0.000*

Comorbidities
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Comorbidities

Angina

0.11 (0.027, 0.20)

0.010*

Coronary heart disease

0.22 (0.14, 0.30)

0.000*

Heart attack

0.027 (-0.05, 0.11)

0.505

Other heart disease

0.14 (0.085, 0.20)

0.000*

Stroke

-0.0091 (-0.086, 0.068)

0.817

Arthritis

0.11 (0.064, 0.15)

0.000*

Emphysema

-0.047 (-0.15, 0.059)

0.384

High blood pressure

0.46 (0.41, 0.51)

0.000*

This model included race/ethnicity, health insurance coverage status as main predictors. The
remaining variables were included as covariates (age, gender, education, region, MSA status,
marital status, family size, poverty level, general health perception, and comorbidities).
“Referent” refers to the comparison group.
“*” Statistically significant at p<0.05.
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